Drug treatment of hypertension

British Medical Journal

Volumn 326, Issue 7380, 2003, Pages 61-62

  Williams, Bryan ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; LISINOPRIL; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDEMA; EDITORIAL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 0037431734     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.326.7380.61     Document Type: Editorial

References (10)

1. Ezzati M, Lopez AD, Rodgers A, Vander Hoom S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60.
2. Collaboration Blood Pressure Lowering Treatment Trialists. Effects of angiotensin converting enzyme inhibitors, calcium antagonists and other blood pressure lowering drugs on mortality and major cardiovascular morbidity. Lancet 2000;356:1955-64.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
4. The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomly assigned to doxazosin vs chlorthalidone: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;283:1967-75.
5. Ramsay LE, Williams B, Johnston DG, MacGregor GA, Poston L, Potter JF, et al. British Hypertension Society guidelines for hypertension management 1999: a summary. BMJ 1999;319:630-5.
6. Cutler JA. Calcium channel blockers for hypertension - uncertainty continues. N Eng J Med 1998;338:679-81.
7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Eng J Med 2000;342:145-53.
8. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002;324:699.
9. Williams B. The renin-angiotensin system and cardiovascular disease: hope or hype? JRAAS 2000;1:142-6.
10. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-405.